{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Maximum+Tolerated+Dose&page=8",
    "query": {
      "condition": "Maximum Tolerated Dose",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 254,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Maximum+Tolerated+Dose&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Maximum+Tolerated+Dose&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T08:48:01.642Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03332355",
      "title": "Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "PAC-1 Compound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanquish Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-10-01",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332355"
    },
    {
      "nct_id": "NCT00124189",
      "title": "Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphoproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "GRN163L",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Geron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2005-07",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2015-12-24",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Hackensack, New Jersey • Buffalo, New York + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00124189"
    },
    {
      "nct_id": "NCT00002218",
      "title": "A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CI-1012",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Parke-Davis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 6,
      "location_summary": "Palm Springs, California • San Francisco, California • Maitland, Florida + 3 more",
      "locations": [
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002218"
    },
    {
      "nct_id": "NCT01610570",
      "title": "Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Mithramycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 8,
      "start_date": "2012-05-10",
      "completion_date": "2014-05-21",
      "has_results": true,
      "last_update_posted_date": "2018-03-02",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01610570"
    },
    {
      "nct_id": "NCT03226574",
      "title": "Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intractable Cancer Pain"
      ],
      "interventions": [
        {
          "name": "Resiniferatoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-09-01",
      "completion_date": "2020-06-18",
      "has_results": false,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Boston, Massachusetts • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03226574"
    },
    {
      "nct_id": "NCT04797468",
      "title": "A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "HLX23",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Henlius Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-07-18",
      "completion_date": "2023-01-13",
      "has_results": false,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Orange, California • Orange City, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04797468"
    },
    {
      "nct_id": "NCT01519817",
      "title": "Cancer Vaccine Targeting Brachyury Protein in Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Malignant Solid Tumors",
        "Colon Neoplasms",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "GI-6301 (Yeast Brachyury Vaccine)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 34,
      "start_date": "2012-01-05",
      "completion_date": "2016-09-01",
      "has_results": true,
      "last_update_posted_date": "2018-01-29",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01519817"
    },
    {
      "nct_id": "NCT00394446",
      "title": "Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Solid Tumors"
      ],
      "interventions": [
        {
          "name": "MPC-6827",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrexis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2005-03",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2008-02-13",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00394446"
    },
    {
      "nct_id": "NCT00220649",
      "title": "Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Luke's-Roosevelt Hospital Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2004-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-08-17",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220649"
    },
    {
      "nct_id": "NCT00842335",
      "title": "A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "JI-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jubilant Innovation Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2009-02",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-11-12T08:48:01.642Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842335"
    }
  ]
}